6
Clinical Trials associated with rDEN2delta30-7169 vaccine(National Institute of Allergy & Infectious Diseases)Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge
The purpose of this study is to evaluate the ability of a single dose of a live attenuated recombinant tetravalent dengue vaccine (TetraVax-DV-TV003, referred to as TV003) to protect against infection with a controlled human infection strain of either DENV-2 (rDEN2Δ30-7169) or DENV-3 (rDEN3Δ30) in adults 18 to 50 years of age with no history of previous flavivirus infection.
A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority. This study will evaluate the ability of a single dose of a trivalent dengue vaccine to protect against infection with an attenuated candidate DENV-2 vaccine, administered 6 months after the trivalent dengue vaccine.
Evaluation of the Clinical and Immune Response Generated by Heterologous Attenuated Dengue Virus Infection
Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority. This study will evaluate the immunologic and clinical response to two dengue vaccines, given 9 months apart, in healthy adults with no history of previous flavivirus infection.
100 Clinical Results associated with rDEN2delta30-7169 vaccine(National Institute of Allergy & Infectious Diseases)
100 Translational Medicine associated with rDEN2delta30-7169 vaccine(National Institute of Allergy & Infectious Diseases)
100 Patents (Medical) associated with rDEN2delta30-7169 vaccine(National Institute of Allergy & Infectious Diseases)
100 Deals associated with rDEN2delta30-7169 vaccine(National Institute of Allergy & Infectious Diseases)